Amgen (BUE:AMGN) Change In Other Working Capital

: ARS59,692 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

Amgen's Change In Other Working Capital for the quarter that ended in Dec. 2023 was ARS59,565 Mil. It means Amgen's Other Working Capital increased by ARS59,565 Mil from Sep. 2023 to Dec. 2023 .

Amgen's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was ARS60,287 Mil. It means Amgen's Other Working Capital increased by ARS60,287 Mil from Dec. 2022 to Dec. 2023 .

Amgen Change In Other Working Capital Historical Data

The historical data trend for Amgen's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Other Working Capital

24,268.08

90,494.56

-28,782.15

29,003.45

60,287.00

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Other Working Capital																-76,448.40	-167,719.95	283,680.00	-115,833.45	59,565.00

Amgen Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS59,692 Mil.

Amgen Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Amgen's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.